Carbimazole
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00389 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | KG + DL |
| 2 | neonatal thyrotoxicosis | KG + DL |
| 3 | hyperthyroxinemia | KG + DL |
| 4 | Prinzmetal angina | KG + DL |
| 5 | autoimmune thyroid disease | KG + DL |
| 6 | Hashimoto thyroiditis | KG + DL |
| 7 | Raynaud disease | KG + DL |
| 8 | migraine with brainstem aura | KG + DL |
| 9 | kyphoscoliotic heart disease | KG + DL |
| 10 | migraine disorder | KG + DL |
| 11 | peripheral vascular disease | KG + DL |
| 12 | heparin cofactor 2 deficiency | KG + DL |
| 13 | antithrombin deficiency type 2 | KG + DL |
| 14 | primary hereditary glaucoma | KG + DL |
| 15 | pulmonary hypertension | KG + DL |
| 16 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 17 | intracranial arteriosclerosis | KG + DL |
| 18 | open-angle glaucoma | KG + DL |
| 19 | peripheral arterial disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.